Ardelyx, Inc.

Ardelyx, Inc. Earnings Recaps

ARDX Health Care 1 recap
Q3 2025 Oct 31, 2025

Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.

Key takeaways
  • Total product revenue reached $105.5 million, a 15% increase year-over-year.
  • IBSRELA generated $78.2 million, a record high, with an upward revision of revenue guidance to $270-$275 million for the year.
  • XPHOZAH contributed $27.4 million in revenue, reflecting a 9% increase from the previous quarter.
  • Introduction of ARDX-10531, a next-generation NHE3 inhibitor, marks a significant step in expanding the company’s pipeline.
  • Strong leadership addition with Sue Hohenleitner as CFO, enhancing financial and strategic insights.
Full recap